First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)
Lindsey R. Baden(Brigham and Women's Hospital), Dan H. Barouch(Beth Israel Deaconess Medical Center), Lauren Peter(Beth Israel Deaconess Medical Center), Jon A Gothing(Brigham and Women's Hospital), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Chelsea Bleckwehl, Peter Abbink(Beth Israel Deaconess Medical Center), Edith Swann(National Institutes of Health), Shringkhala Bajimaya(Beth Israel Deaconess Medical Center), Mark Wolff(Emmes (United States)), Brian A. Engelson, Avinash Oza, Brittany R. Carey(Hadassah Medical Center), Mo Weijtens(Janssen (Netherlands)), Maria Grazia Pau, Michael S. Seaman(Beth Israel Deaconess Medical Center), Robert Tucker(Brigham and Women's Hospital), Jennifer Johnson(Northwestern University), Jane A. Kleinjan(Brigham and Women's Hospital), Raphael Dolin(Beth Israel Deaconess Medical Center), Meghan Kunchai(Emmes (United States))
Cited by 30
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
|Science|2020|1.1k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k